Trial · NCT03478982
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 Hours | Open-label: Staccato Alprazolam (STAP-001) 1.0 Milligram (mg) | 62.5 | percentage of participants | ||
| Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 Hours | Double-blind: Placebo | 42.5 | percentage of participants | ||
| Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 Hours | Double-blind: Staccato Alprazolam 1.0 mg | 65.8 | percentage of participants | ||
| Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 Hours | Double-blind: Staccato Alprazolam 2.0 mg | 65.8 | percentage of participants | ||
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Open-label: Staccato Alprazolam (STAP-001) 1.0 Milligram (mg) | Much worse than | 0 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Placebo | Much worse than | 2.5 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Staccato Alprazolam 1.0 mg | Much worse than | 0 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Staccato Alprazolam 2.0 mg | Much worse than | 0 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Open-label: Staccato Alprazolam (STAP-001) 1.0 Milligram (mg) | Worse than | 0 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Placebo | Worse than | 5.0 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Staccato Alprazolam 1.0 mg | Worse than | 2.6 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Staccato Alprazolam 2.0 mg | Worse than | 5.3 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Open-label: Staccato Alprazolam (STAP-001) 1.0 Milligram (mg) | Same as | 12.5 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Placebo | Same as | 42.5 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Staccato Alprazolam 1.0 mg | Same as | 57.9 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Staccato Alprazolam 2.0 mg | Same as | 55.3 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Open-label: Staccato Alprazolam (STAP-001) 1.0 Milligram (mg) | Better than | 50.0 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Placebo | Better than | 35.0 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Staccato Alprazolam 1.0 mg | Better than | 18.4 | percentage of participants | |
| Percentage of Participants With Seizure Episode Severity Assessed by Seizure Episode Severity Scale | Double-blind: Staccato Alprazolam 2.0 mg | Better than | 28.9 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03478982/results